Science Corporation’s brain tech is worth $3.5 billion after new funding
- ID
- 47340
- Status
- summarized
- Published
- 17 Nov 2026, 10:26 PM
- Fetched
- 18 Nov 2026, 1:46 AM
- Provider
- TechCrunch
- Category
- technology
- Original URL
- https://techcrunch.com/2026/11/17/science-corporations-brain-tech-is-worth-3-5-billion-after-new-funding/
- Source URL
- https://techcrunch.com/feed/
Summary
- Score
- 2.0
- Created
- 18 Nov 2026, 1:47 AM
- Tags
- Audience
- saas_startup_founders
What happened
Science Corporation raised a $400 million Series D at a reported $3.5 billion valuation, with investors including Khosla Ventures, Y Combinator, Tenet Healthcare, and others. Its PRIMA chip, approved in Europe and available in Germany for age-related macular degeneration, is now being trialled for Stargardt’s disease, and the company plans a US FDA Humanitarian Device Exemption path. It is also designing human trials for a bio-hybrid sensor made from cultured neurons and silicon with Yale neurosurgery professor Murat Günel, targeting conditions such as Parkinson’s.
Why it matters
For Malaysian software, AI, and startup builders there is no direct tooling, cloud, payment, policy, or developer-platform change to act on; the concrete items are a $400 million medtech round, European approval for PRIMA, and an FDA Humanitarian Device Exemption route. If you track fundraising or regulated-market strategy, note the approval-first path, but do not treat this as an AI/developer signal.
Discussion angle
Compare the regulatory moat: PRIMA needed European approval and an FDA Humanitarian Device Exemption route before US use—what could SEA founders learn from choosing regulated markets where approval itself is the defensible asset?